Gene targeting in adult organs using in vivo cleavable donor plasmids for CRISPR-Cas9 and CRISPR-Cas12a

被引:2
|
作者
Ishibashi, Riki [1 ,2 ]
Maki, Ritsuko [1 ]
Toyoshima, Fumiko [1 ,2 ,3 ]
机构
[1] Kyoto Univ, Inst Life & Med Sci, Dept Biosyst Sci, Sakyo Ku, Kyoto 6068507, Japan
[2] Kyoto Univ, Grad Sch Biostudies, Dept Mammalian Regulatory Networks, Sakyo Ku, Kyoto 6068502, Japan
[3] Tokyo Med & Dent Univ TMDU, Med Res Inst, Dept Homeostat Med, Bunkyo Ku, Yushima, Tokyo 1138510, Japan
基金
日本学术振兴会;
关键词
HYDRODYNAMIC INJECTION; RNA INTERFERENCE; HIGH-LEVEL; NAKED DNA; EXPRESSION; GENOME; DELIVERY; HEPATOCYTES; LIVER; CPF1;
D O I
10.1038/s41598-024-57551-8
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The CRISPR-Cas system for in vivo genome editing is a powerful tool for gene therapy against several diseases. We have previously developed the pCriMGET_9-12a system, an in vivo cleavable donor plasmid for precise targeted knock-in of exogenous DNA by both Cas9 and Cas12a. Here, we show that the pCriMGET_9-12a system can be applied for in vivo in-frame knock-in of exogenous DNA in adult mouse liver by hydrodynamic delivery of the targeting plasmids. The in vivo cleavable pCriMGET_9-12a donor plasmids significantly increased the knock-in efficiency of both CRISPR-Cas9 and CRISPR-Cas12a in the adult mouse liver compared to uncleavable donor plasmids. This strategy also achieved in-frame reporter gene knock-in without indel mutations. Therefore, in vivo gene targeting using the pCriMGET_9-12a system may contribute to the establishment of safer, more precise, versatile and efficient gene therapy methods in adult organs.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Inducible in vivo genome editing with CRISPR-Cas9
    Lukas E Dow
    Jonathan Fisher
    Kevin P O'Rourke
    Ashlesha Muley
    Edward R Kastenhuber
    Geulah Livshits
    Darjus F Tschaharganeh
    Nicholas D Socci
    Scott W Lowe
    Nature Biotechnology, 2015, 33 : 390 - 394
  • [32] CRISPRscan: designing highly efficient sgRNAs for CRISPR-Cas9 targeting in vivo
    Miguel A Moreno-Mateos
    Charles E Vejnar
    Jean-Denis Beaudoin
    Juan P Fernandez
    Emily K Mis
    Mustafa K Khokha
    Antonio J Giraldez
    Nature Methods, 2015, 12 : 982 - 988
  • [33] CRISPRscan: designing highly efficient sgRNAs for CRISPR-Cas9 targeting in vivo
    Moreno-Mateos, Miguel A.
    Vejnar, Charles E.
    Beaudoin, Jean-Denis
    Fernandez, Juan P.
    Mis, Emily K.
    Khokha, Mustafa K.
    Giraldez, Antonio J.
    NATURE METHODS, 2015, 12 (10) : 982 - 988
  • [34] Acute gene inactivation in the adult mouse liver using the CRISPR-Cas9 technology
    Wang, Xiao
    Xu, Bo-Lin
    Chen, Xiao-Wei
    STAR PROTOCOLS, 2021, 2 (03):
  • [35] Gene Editing of Human Hepatocytes by CRISPR-Cas9
    Zhang, Qingshuo
    Tiyaboonchai, Amita
    Balaji, Niveditha
    Naugler, Willscott
    Grompe, Markus
    MOLECULAR THERAPY, 2018, 26 (05) : 367 - 367
  • [36] Safeguarding CRISPR-Cas9 gene drives in yeast
    James E DiCarlo
    Alejandro Chavez
    Sven L Dietz
    Kevin M Esvelt
    George M Church
    Nature Biotechnology, 2015, 33 : 1250 - 1255
  • [38] The MyLO CRISPR-Cas9 toolkit: a markerless yeast localization and overexpression CRISPR-Cas9 toolkit
    Bean, Bjorn D. M.
    Whiteway, Malcolm
    Martin, Vincent J. J.
    G3-GENES GENOMES GENETICS, 2022, 12 (08):
  • [39] Unraveling the potential of CRISPR-Cas9 for gene therapy
    Barrangou, Rodolphe
    May, Andrew P.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (03) : 311 - 314
  • [40] CRISPR-cas9 Gene Editing for Cystic Fibrosis
    Xia, Emily
    MOLECULAR THERAPY, 2019, 27 (04) : 196 - 196